Muscle loss in kidney disease: could amino acids be the answer?
NCT ID NCT07437053
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study tests whether two types of amino acids (protein building blocks) can safely improve muscle mass and strength in 20 adults aged 45-75 with advanced chronic kidney disease and sarcopenia (muscle loss). Participants will take the supplements for 6 weeks while researchers measure handgrip strength, muscle mass, and walking speed. The goal is to find a way to combat muscle loss without needing a high-protein diet, which is often restricted in kidney disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Ability of participant to understand and the willingness to sign a written informed consent document. 2. Males and females of age 45-75 yrs 3. Hand grip strength of \<26 kg for male and \<16 kg for female 4. Documented diagnosis of estimated glomerular filtration rate (eGFR) of ≤15 mL/min/1.73 m2, based on CKD-EPI serum-creatinine based formula in the past ≥3 months in absence of acute kidney injury. 5. Not on dialysis and is not expected to initiate dialysis or any kidney replacement therapy in next 4 months 6. Receiving standard of care including dietary recommendation for diabetes, hypertension, CKD, and other comorbidities 7. Patients who are on an SGLT2-i or GLP-1 agonist should be on a stable dose for at least 3 months prior randomization, with no dose adjustments expected in the next 4 months 8. Serum HCO3 concentration 20-29 mmol/L based on two consecutive recent routine labs 9. HbA1c 7-9% based on most recent routine lab 10. Serum albumin ≥3.8 g/dL based on most recent routine lab 11. Blood hemoglobin ≥10 g/dL based on most recent routine lab 12. Willingness to adhere to lifestyle management, including diet and exercise as recommended by care providers, and to the study intervention, procedures, and regimen. Exclusion Criteria: 1. Any known history of hypersensitivity/intolerance to valine or specific amino acids 2. Any condition that may indicate the individual is not "metabolically stable" which may include active infection, currently on systemic antibiotic, hospitalization within 2 weeks on consenting, active malignancy, on immunosuppressive agents, and unexplained significant weight loss during the past 3 months 3. With a cardiac pacemaker and/or an implantable cardioverter-defibrillator 4. Significant arthritis prohibiting strength test and walk gait speed test 5. Significant comorbidities including heart failure (NY Class III or IV), neurological disorders, HIV AIDS, etiology of CKD other than diabetes and hypertension, or any condition that could compromise the subject's ability to study procedures as judged by study clinician 6. Currently taking any protein supplements 7. Pregnant, lactating, childbearing women 8. History of Maple syrup urine disease (MSUD) 9. Scheduled for kidney transplantation or dialysis in next 4 months 10. Current participation in another interventional trial 11. Documented noncompliance with regard to clinic visits, medications, and lifestyle management. 12. Documentation of current or history of substance abuse.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Can a Patient's own kidney cells hold off dialysis?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Two drugs, one goal: can finerenone or semaglutide cut kidney damage markers?
- One team, three conditions: can coordinated care tame heart, kidney, and diabetes?